Myriad Genetics Inc reports results for the quarter ended in June - Earnings Summary

Myriad Genetics

04/08/2023 24:27

* Myriad Genetics Inc  MYGN.OQ  reported a quarterly
adjusted loss
of 8 cents​​ per share for the quarter ended in June. The mean
expectation of nine analysts for the quarter was for a loss of 8
cents per share.
    * Revenue rose 2.3% to $183.50 million from a year ago;
analysts
expected $187.13 million. 
    * Myriad Genetics Inc's reported EPS for the quarter was a
loss of
$1.42​.
    * The mean earnings estimate of analysts had fallen by
about 0.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Myriad Genetics Inc shares had fallen by 8.2% this
quarter and
gained 46.7% so far this year.
    * The company reported a quarterly loss of $116.1 million.
    * Wall Street's median 12-month price target for Myriad
Genetics
Inc is $24.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 3 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 3 at 11:26 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.08          -0.08          Met
 Mar. 31 2023      -0.19          -0.21          Missed
 Dec. 31 2022      -0.16          -0.12          Beat
 Sep. 30 2022      -0.06          -0.19          Missed